"The average person will never get the chance to invest in a future unicorn like Moderna: The type of private equity deals that brought the now-famous biotech to the world are done in country clubs and coffee houses in a select few places, leaving anyone who is not a hedge fund manager, venture capitalist or disgustingly rich individual out of the game."
Continue Reading >The Bioverge Reg CF Offering is Officially Live 🎊 and Accepting Investments!
Continue Reading >Even as venture capital last year poured $28.5 billion into biotech companies globally and biotech IPOs raised more than $5 billion in the first quarter of this year alone, Neil Littman says he saw both a disturbing trend, as well as a potential opportunity. Investors focused more capital into larger ...
Continue Reading >Neil Littman is the Founder of Bioverge, a highly curated impact investment platform exclusively dedicated to healthcare. Bioverge enables a motivated public to finance and support the health-related causes and companies most important to them. Previously, Neil was a member of the Executive Leadership Team and Director ...
Continue Reading >As part of our series about “5 Things I Need To See Before Making A VC Investment”, I had the pleasure of interviewing Neil J. Littman, MS. He has comprehensive healthcare-specific financial experience in venture capital, business development, and investment banking. As a member of the Executive Leadership Team and ...
Continue Reading >Neil Littman is the CEO and Founder of Bioverge Inc. Bioverge is an investment platform that funds visionary entrepreneurs with the aim of transforming healthcare and bringing science fiction to life. In this episode of MedStreet Journal, Neil Littman shares what he’s working on in Bioverge, his experiences in the healthcare industry and how it led him towards creating a company with an entrepreneurial management team skilled in venture creation as well as science.
Continue Reading >